Odanacatib Uses, Dosage, Side Effects, Food Interaction and all others data.

Odanacatib is an inhibiter of cathepsin K which was originally developed be Merck & Co as a new treatment for osteoporosis . The drug made it to phase III trials before abandoned due to increased stroke.

Increases bone mineral density and reduces risk of fractures in osteoporosis .

Trade Name Odanacatib
Generic Odanacatib
Odanacatib Other Names Odanacatib
Formula C25H27F4N3O3S
Weight Average: 525.56
Monoisotopic: 525.170925567
Protein binding

97.5% bound to plasma proteins .

Groups Investigational
Therapeutic Class
Available Country
Last Updated: September 19, 2023 at 7:00 am


Investigated for use/treatment in osteoporosis .

How Odanacatib works

Odanacatib inhibits cathepsin K, likely by binding to its active site . Cathepsin K is a cysteine protease enzyme which is secreted by osteoclasts . Cathepsin K is responsible for the breakdown of collagen in the bone matrix as part of bone resorption. The inhibition of this enzyme results in decreased bone resorption without affecting bone deposition resulting in increased bone mineral density. This increased bone mineral density strengthens the bone which leads to fewer fractures in osteoporosis.


Odanacatib was found to increase the risk of stroke . No further toxicological studies have been performed.

Volume of Distribution


Elimination Route

Tmax of 2-6h . The absolute bioavailabilities observed with 30mg and 50 mg doses are 70% and 30% respectively. When taken with high fat meals the 50mg dose's bioavailability increases to 49% and tmax increases to 10.5h .

Half Life

Apparent half life observed to be 87.3-94.7h .


Total clearance of 0.8L/h .

Elimination Route

16.9% excreted in urine. 74.5% excreted in feces.

Innovators Monograph

You find simplified version here Odanacatib

*** Taking medicines without doctor's advice can cause long-term problems.